These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 6547167

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [Abstract] [Full Text] [Related]

  • 3. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA, Hum GJ, Sheehan WW, Ryden VM, Bateman JR.
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [Abstract] [Full Text] [Related]

  • 4. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, Ternberg JL, Behm FG, Wharam MD, Chauvenet AR.
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease.
    Fuller LM, Hagemeister FB.
    Recent Results Cancer Res; 1989 Aug; 117():197-204. PubMed ID: 2602645
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
    Schellong G, Riepenhausen M, Creutzig U, Ritter J, Harbott J, Mann G, Gadner H.
    J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC.
    N Engl J Med; 1993 Apr 08; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract] [Full Text] [Related]

  • 15. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
    Canellos GP.
    Leukemia; 1996 Jun 08; 10 Suppl 2():s68. PubMed ID: 8649055
    [No Abstract] [Full Text] [Related]

  • 16. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey.
    Marmor D, Duyck F.
    Andrologia; 1995 Jun 08; 27(2):99-106. PubMed ID: 7598233
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease.
    Cunningham J, Mauch P, Rosenthal DS, Canellos GP.
    Cancer Treat Rep; 1982 Apr 08; 66(4):1015-22. PubMed ID: 7074629
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.